Core Viewpoint - The news highlights the strengthening of Shaanxi state-owned stocks, particularly the surge in Xi'an Catering, following the introduction of 16 measures by the Shaanxi provincial government aimed at deepening capital market reforms to support high-quality development in the region [1] Group 1: Policy Measures - The Shaanxi provincial government has introduced 16 measures to enhance capital market reforms, focusing on supporting high-quality development [1] - Key measures include promoting major asset restructuring for state-controlled listed companies with poor operational efficiency [1] - The government aims to establish a stable, timely, and predictable cash dividend mechanism for listed companies, encouraging higher levels and frequencies of cash dividends [1] Group 2: Market Management - Listed companies are encouraged to conduct compliant market value management, utilizing share buybacks and other methods to enhance reasonable valuation levels [1] - The focus is on critical sectors such as new generation information technology, artificial intelligence, aerospace, new energy, new materials, high-end equipment, biomedicine, and quantum technology [1] - The government supports quality A-share listed companies to achieve secondary listings on the Hong Kong Stock Exchange in an "A+H" share format [1]

Core Viewpoint - BeiGene's stock price has shown significant growth this year, with a year-to-date increase of 80.72%, indicating strong market performance and investor interest [1][2]. Group 1: Stock Performance - As of November 27, BeiGene's stock price reached 291.00 CNY per share, with a trading volume of 4.60 billion CNY and a market capitalization of 448.34 billion CNY [1]. - The stock has experienced a 2.62% increase over the last five trading days, a 3.26% increase over the last twenty days, and an 18.29% increase over the last sixty days [1]. - The company has appeared on the "龙虎榜" (a stock trading list) once this year, with the most recent appearance on September 2 [1]. Group 2: Financial Performance - For the period from January to September 2025, BeiGene reported a revenue of 27.595 billion CNY, reflecting a year-on-year growth of 44.21% [2]. - The net profit attributable to shareholders for the same period was 1.139 billion CNY, showing a substantial year-on-year increase of 130.88% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of BeiGene's shareholders increased to 36,200, a rise of 55.33% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 35.79% to 3,195 shares [2]. - Notable changes in institutional holdings include a decrease in shares held by several major shareholders, with new entries from others [2].

Core Viewpoint - Nocera Biopharma has seen significant stock price growth this year, with a 112.95% increase, indicating strong market performance and investor interest [2]. Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [2]. - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and R&D services [2]. Stock Performance - As of November 27, the stock price reached 26.15 CNY per share, with a market capitalization of 46.145 billion CNY [1]. - The stock has experienced a recent increase of 8.19% over the last five trading days and a 14.69% increase over the last 20 days, although it has declined by 8.28% over the past 60 days [2]. Financial Performance - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion CNY, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was -64.4149 million CNY, showing a 76.61% increase in losses compared to the previous period [3]. - As of September 30, 2025, the number of shareholders increased by 8.66% to 16,500, indicating growing investor interest [3]. Institutional Holdings - As of September 30, 2025, notable institutional shareholders include: - Fuguo Precision Medical Flexible Allocation Mixed A, holding 12.1549 million shares, down 427,100 shares from the previous period [3]. - Wanjia Preferred, a new shareholder with 10 million shares [3]. - Ping An Medical Health Mixed A, also a new shareholder with 8.6266 million shares [3].

Core Insights - The Chinese Academy of Sciences has established 10 major scientific infrastructure projects in Guangdong, with 5 set to commence operations this year [1][2]. Group 1: Infrastructure Development - The ongoing projects include significant facilities such as the Accelerator-Driven Transmutation, the Second Phase of the China Spallation Neutron Source, and Advanced Attosecond Laser Facilities, among others [2][3]. - These infrastructures are crucial for supporting original innovation and breaking through key core technologies, aiming to secure a leading position in technology [2]. Group 2: Collaboration and Innovation - The Chinese Academy of Sciences has collaborated closely with the Guangdong Provincial Department of Science and Technology, organizing over 30 matchmaking events involving more than 50 research institutions and over 800 enterprises [2]. - This initiative aims to bridge the gap between research teams and technology enterprises, effectively promoting the integration of scientific and industrial innovation [2]. Group 3: Upcoming Events - A significant showcase of the achievements of these infrastructures will take place at the upcoming 2025 Greater Bay Area Science Forum, where the results of the innovation development will be presented [3]. - Additionally, a technology achievement matchmaking conference will be held, focusing on seven key areas including artificial intelligence and new energy storage [3].

11月20日，由德国因戈尔施塔特市、商务部投资促进事务局、中华人民共和国驻慕尼黑总领事馆共同主 办，巴伐利亚中国中心、中国国际投资促进中心（德国）承办的第十一届巴伐利亚中国日在因戈尔施塔 特成功举行。本届活动聚焦中德生命健康产业合作，吸引了来自政府、科研和企业界的百余名代表参 会。 因戈尔施塔特市市长迈克尔·科恩表示，因市与中国长期保持良好合作，在制造业与科研领域基础坚 实。当前因市正推进产业转型，生命健康产业成为重点方向，与中国发展优势高度契合。他欢迎更多中 国企业与机构参与因市创新生态，共同拓展新的合作机遇。 商务部投资促进事务局局长刘民强指出，中德经贸合作对全球产业链稳定意义重大，两国领导人已为未 来合作指明方向。中国经济持续释放高质量发展和开放红利，生命健康、生物医药和人工智能正成为合 作新亮点。投资促进局将继续为双方企业提供专业服务，推动更多项目落地。 德国巴伐利亚州经济部总司长王猛博士强调，中国是巴州第一大贸易伙伴，双方在制造业和生命科学领 域优势互补。巴州具备领先的科研体系和生命健康创新生态，始终欢迎中国企业投资发展。他表示，愿 推动双方在科研、产业与人才交流等方面进一步深化合作。 中国驻慕尼黑 ...

上海科创基金是上海国际集团根据上海市委、市政府部署要求，在2017年发起设立的全国首家以服务上 海科创中心建设为核心使命的市场化母基金，成立8年来已累计管理规模超170亿元，投资子基金超100 只，带动子基金管理总规模超2500亿元，培育上市企业166家、国家级专精特新"小巨人"企业超500家。 业内人士表示，此次通过QFLP渠道引入丰隆星河的国际资本，正是上海市国资委支持科创基金实现专 业化升级、产品化创新与生态化延展的重要举措，将有效拓宽上海科创企业融资渠道，为成长期硬科技 企业提供稳定资金支持。同时，丰隆集团的国际产业资源与投资视野，将助力被投企业对接全球市场、 技术与人才，加速科技成果转化，推动人工智能、生物医药等关键领域形成产业集群优势。 近日，上海科创基金与新加坡丰隆星河在沪签订QFLP合作暨上海科创三期基金投资意向协议。丰隆星 河拟设立5亿元规模QFLP基金，专项投资上海科创三期基金。此次丰隆星河通过QFLP渠道投资上海科 创基金，开创了境外企业家以个人名义设立QFLP基金参与上海科创中心建设的先例，将成为国际长期 资本参与上海科创中心建设可复制、可推广的一次成功案例。 此次合作是上海市国资委落 ...

过去一周，科技与制造领域以超30起案例、多笔亿元级交易成融资核心：AI赛道星动纪元获近10亿元A +轮融资；半导体与高端制造领域寒驰科技等获千万 至亿元级融资；商业航天新秀星际光遥获近亿元天使轮融资。 医疗健康领域稳健发力，大额交易频现：瑞普晨创获5亿元A +轮融资，拓济医药斩获6000万美元 Pre-A +轮融资，资金聚焦再生医学等赛道，创新器械领域 明澈生物等细分场景企业获资本加持。 消费服务案例虽少但龙头亮眼，仙饼嫂、兰 LAN等获投。整体印证"硬科技 + 生物医药"双主线，多赛道协同格局清晰。 21创投不完全统计，11月17日—11月23日，报告日期内国内一级市场发生融资事件36起。其中，有31笔融资披露了融资金额和币种信息，总规模约合人民币 45.5亿元人民币。 | 创投 | | 2025年6月2日-6月8日 国内一级市场投融资币种分布 | | --- | --- | --- | | | 市种 | 案例数(起) | | | 人民币 | 31 | | | | 注: 数据由21创投根据公开报道整理 | 01、先进制造、人工智能赛道完成多笔融资 本周融资数量最多的行业领域仍是科技与制造。在三大行业领域的诸 ...

21创投不完全统计，11月17日—11月23日，报告日期内国内一级市场发生融资事件36起。其中，有31笔 融资披露了融资金额和币种信息，总规模约合人民币45.5亿元人民币。 过去一周，科技与制造领域以超30起案例、多笔亿元级交易成融资核心：AI赛道星动纪元获近10亿元A +轮融资；半导体与高端制造领域寒驰科技等获千万至亿元级融资；商业航天新秀星际光遥获近亿元天 使轮融资。 医疗健康领域稳健发力，大额交易频现：瑞普晨创获5亿元A +轮融资，拓济医药斩获6000万美元 Pre-A +轮融资，资金聚焦再生医学等赛道，创新器械领域明澈生物等细分场景企业获资本加持。 消费服务案例虽少但龙头亮眼，仙饼嫂、兰 LAN等获投。整体印证"硬科技 + 生物医药"双主线，多赛 道协同格局清晰。 01、先进制造、人工智能赛道完成多笔融资 本周融资数量最多的行业领域仍是科技与制造。在三大行业领域的诸多赛道中，先进制造赛道完成10笔 融资，融资金额约为10.5亿元人民币；生物医药赛道完成7笔融资，披露融资额约7.5亿元人民币；人工 智能赛道完成4笔融资，披露金额约为7.6亿元。 02、北京市、上海市、广东省完成多笔融资 从披露获投企业的 ...

11月24日至25日，2025长沙市高价值专利运营大赛（以下简称"2025长高赛"）决赛在长沙举办。40 项具有重要技术与市场价值的高价值专利项目同台竞技，覆盖人工智能、生物医药、新能源、高端装备 等多个战略性新兴产业，充分展现了长沙在关键领域的创新实力与专利转化成果，为区域科技创新和产 业升级注入新动能。 大赛颁奖典礼拟于12月举行，届时将正式公布各组别获奖名单并颁奖。"后续将围绕获奖项目持续开展 资本对接、产业合作等多端口赋能工作，推动优秀成果在长沙落地生根、开花结果。"大赛组委会相关 负责人介绍，组委会还将建立项目跟踪与服务机制，通过政策倾斜、资源导入、孵化加速等多元化支持 手段，助力创新主体跨越从成果到产品、从专利到产业的关键阶段，逐步构建起"挖掘—培育—转化— 赋能"的全链条专利运营服务体系。 据了解，作为长沙市首次聚焦高价值专利运营的专业赛事，2025长高赛设置了企业组、高校院所组和大 学生创新创业组3个竞赛组别，生动展现了从技术萌芽到市场应用的全周期创新生态。大赛现场组织了 长投控股、东方产投、三泽创投、长财科技、德瑞基金、长沙犀灵舸等多家投融资机构现场观摩，并为 有意向的项目方安排一对一对接洽 ...

11月26日，金花股份（维权）盘中下跌2.00%，截至09:48，报8.80元/股，成交7789.66万元，换手率 2.34%，总市值32.85亿元。 资金流向方面，主力资金净流出213.40万元，特大单买入103.51万元，占比1.33%，卖出393.07万元，占 比5.05%；大单买入1455.70万元，占比18.69%，卖出1379.54万元，占比17.71%。 金花股份所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：中药、抗流感、小盘、生物 医药、医疗器械等。 截至9月30日，金花股份股东户数2.01万，较上期减少2.22%；人均流通股18574股，较上期增加2.27%。 2025年1月-9月，金花股份实现营业收入3.84亿元，同比减少8.36%；归母净利润3448.12万元，同比增长 12.06%。 分红方面，金花股份A股上市后累计派现1.18亿元。近三年，累计派现1058.14万元。 责任编辑：小浪快报 金花股份今年以来股价涨13.08%，近5个交易日涨8.51%，近20日涨16.87%，近60日涨11.39%。 资料显示，金花企业(集团)股份有限公司位于陕西省西安市高新区高新三路财富 ...